The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
2021 · Nature Communications · 170 citations
https://doi.org/10.1038/s41467-021-25332-w
L
Lars Ny
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
268
Papers
4.8K
Citations
38
h-index
81
i10-index
Lars Ny is an academic researcher from Sahlgrenska University Hospital. The author has contributed to research in topics: Immunotherapy and Immune Responses & Ocular Oncology and Treatments & Cancer Immunotherapy and Biomarkers. The author has an h-index of 38, co-authored 228 publications.
ORCID: 0000-0003-3864-5958Papers by this author
worksClinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model
2017 · Nature Communications · 165 citations
https://doi.org/10.1038/s41467-017-00786-z
HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice
2019 · Cancer Research · 127 citations
https://doi.org/10.1158/0008-5472.can-18-3158
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
2022 · Journal of Clinical Oncology · 124 citations
https://doi.org/10.1200/jco.22.00221
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
2019 · BMC Cancer · 72 citations
https://doi.org/10.1186/s12885-019-5623-3
Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis
2021 · Journal for ImmunoTherapy of Cancer · 26 citations
https://doi.org/10.1136/jitc-2021-002732
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat